益生菌临床试验的全球分析。
Global analysis of clinical trials with probiotics.
作者信息
Dronkers Theresia M G, Ouwehand Arthur C, Rijkers Ger T
机构信息
Department of Sciences, University College Roosevelt, Lange Noordstraat 1, 4331 CB, Middelburg, the Netherlands.
DuPont Nutrition and Biosciences, Danisco Sweeteners Oy, Sokeritehtaantie, Kantvik, 02460, Finland.
出版信息
Heliyon. 2020 Jul 17;6(7):e04467. doi: 10.1016/j.heliyon.2020.e04467. eCollection 2020 Jul.
Over 1,000 clinical studies with probiotics, registered at ClinicalTrials.gov and/or the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization, have addressed over 700 different diseases and conditions. The average size of a clinical trial with probiotics (74 participants) is comparable to the overall average of all studies in ClincialTrials.gov. GG (LGG) and ssp. BB12 are the probiotic strains studied most. The exact composition of the product which is used, including the dosage, is not always indicated in the registry. The majority of probiotics studies at ClinicalTrials.gov is registered in the USA or Europe (56%). The data from ICTRP show the rapid expansion of clinical studies with probiotics in Asia, notably Iran and China.
在ClinicalTrials.gov和/或世界卫生组织国际临床试验注册平台（ICTRP）上注册的、超过1000项有关益生菌的临床研究，涉及700多种不同疾病和状况。益生菌临床试验的平均规模（74名参与者）与ClinicalTrials.gov上所有研究的总体平均规模相当。鼠李糖乳杆菌GG（LGG）和嗜热栖热放线菌BB12是研究最多的益生菌菌株。注册信息中并不总是标明所使用产品的确切成分，包括剂量。ClinicalTrials.gov上的大多数益生菌研究是在美国或欧洲注册的（56%）。ICTRP的数据显示，亚洲尤其是伊朗和中国有关益生菌的临床研究正在迅速扩展。
Zotero 插件